The main objective of the project "Determination of cinnamon effects on advanced glycation end products, plasma vascular and systematic inflammation factors, antioxidant status, NF-kB and Sirtuin 1 activity in mononuclear cells in type 2 diabetic patients". This clinical trial is a randomized, double-blind and placebo-controlled. Patients with type II diabetes clinics and medical centers in Tehran referred to the relevant elected in accordance with the inclusion and exclusion criteria. The sample size was estimated for each group of 20 patients, including 10% loss, 22 patients in each group and a total of 44 patients, respectively.
In this study, patients with type II diabetes who are eligible to study the subject, objectives and methodology is explained study, If you wish to participate in this study are patients informed consent is obtained. The patients were divided into 2 groups using random numbers table. In order to execute a double-blind study, at baseline set by anyone other than the researchers encoded packets containing the capsules to lack of knowledge of the capsules received by each group is maintained. The patients in the supplement group capsules of cinnamon, cinnamon supplement capsules at baseline package is for 8 weeks. The patients in the supplement group cinnamon capsules daily 3 grams of cinnamon supplementation (capsules 1 gr cinnamon, 3 times per day) during the study receive 8 weeks. Patients in the control group at baseline capsules packages placebo (microcrystalline cellulose) that are similar to cinnamon supplement capsules for 8 weeks is and the patient is asked to capsules 1 gr microcristalin cellulose, 3 times per day, use .